Literature DB >> 17827460

Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.

Daniel A Hamstra1, Alnawaz Rehemtulla, Brian D Ross.   

Abstract

Imaging of response to oncology treatments, either on clinical protocol or as part of standard practice, is a complicated process that has evolved during the last 10 years due to the improvement of existing imaging technologies and the introduction of newer modalities. Diffusion magnetic resonance imaging is a technique that measures the mobility of water within tissues and, as such, may function as a surrogate marker for both tissue cellularity and response to treatment that occur earlier than usual measures of tumor response. This review highlights the development of this technique and the state of current clinical understanding of its utility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827460     DOI: 10.1200/JCO.2007.11.9610

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  117 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

Review 2.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

3.  Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.

Authors:  Inas S Khayal; Mei-Yin C Polley; Llewellyn Jalbert; Adam Elkhaled; Susan M Chang; Soonmee Cha; Nicholas A Butowski; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-05-25       Impact factor: 12.300

Review 4.  Diffusion-weighted MRI for assessment of early cancer treatment response.

Authors:  Stefanie Galbán; Jean-Christophe Brisset; Alnawaz Rehemtulla; Thomas L Chenevert; Brian D Ross; Craig J Galbán
Journal:  Curr Pharm Biotechnol       Date:  2010-09-01       Impact factor: 2.837

5.  Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Takashi Kato; Masashi Noda; Hidenori Yanagi; Naohiro Tomita; Norihiko Kamikonya; Shozo Hirota
Journal:  Mol Clin Oncol       Date:  2015-07-21

6.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 7.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

8.  Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.

Authors:  Lionel Mignion; Prasanta Dutta; Gary V Martinez; Parastou Foroutan; Robert J Gillies; Bénédicte F Jordan
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

9.  Multimodality imaging of tumor and bone response in a mouse model of bony metastasis.

Authors:  Benjamin A Hoff; Komal Chughtai; Yong Hyun Jeon; Kenneth Kozloff; Stefanie Galbán; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

10.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.